Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of litifilimab in adults with active systemic lupus erythematosus
2021-006378-22Phase 3Active
- Sponsor
- Biogen
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of litifilimab in systemic lupus erythematosus (SLE), sponsored by Biogen. Primary endpoint: Primary safety endpoint. Started Jul 2022; status: active.
02
Drugs
litifilimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2021-006378-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006378-22.